Author: News Room
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a biotech stock for investors seeking to gain oncology exposure. Their flagship research project is CRB-701, a Phase 1 drug that targets Nectin-4-positive solid tumors. CRBP also has other research projects that could be lucrative, but all of them are still in their stages and largely unproven. From a financial perspective, CRBP is running low on funds, with less than a year of cash runway. However, the company recently filed with the SEC to raise up to $300.0 million in additional funds. This will likely cause dilution for investors and burden the balance sheet…
Last updated: April 19, 2024 10:52 EDT | 3 min read Amidst the surging prices of Polkadot and Shiba Inu, BlockDAG is capturing the imagination of the cryptocurrency world with its groundbreaking potential for a 30,000x return on investment. As Polkadot advances its community engagement and Shiba Inu rides a wave of investor enthusiasm, BlockDAG distinguishes itself with a novel blend of blockchain security and Directed Acyclic Graph (DAG) scalability. This innovative approach is highlighted by a teaser for an upcoming keynote video shot from the moon, promising to elevate the project to unprecedented heights. As BlockDAG’s presale gathers momentum, it…
Caitlyn Pratt is an avid Aldi shopper, so much so that she crosses state lines a few times a month, driving 45 minutes from her home in Heavener, Oklahoma to the nearest Aldi in neighboring Arkansas. The distance doesn’t bother her if it means she can do these three things: Stay within budget for her household needs, skip Walmart, and most importantly, indulge in a fun little affordable treasure hunt in a place that Aldi superfans have dubbed the “aisle of shame.” Aldi, a privately-held German discount grocer that touts a Walmart-like sales pitch of everyday low prices, has operated…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. Both the S & P 500 index and the Nasdaq Composite fell Friday and were on pace for their sixth consecutive negative days. The Dow Jones Industrial was up slightly, but still likely to end the week in the red. No surprise then that the S & P 500 Short Range Oscillator indicates the market is still very much in oversold territory. That doesn’t mean investors should jump and buy stocks indiscriminately. Instead, Jim Cramer…
Citadel Securities ripped Trump Media CEO Devin Nunes on Friday for a letter he sent the Nasdaq Stock Market which mentioned Citadel Securities and other major market companies after warning of possible illegal short sale trading in DJT shares.”Devin Nunes is the proverbial loser who tries to blame ‘naked short selling’ for his falling stock price,” a spokesperson for Citadel Securities said.”Nunes is exactly the type of person Donald Trump would have fired on The Apprentice,” said the spokesperson referring to the former Republican president’s business competition reality TV show.”If he [Nunes] worked for Citadel Securities, we would fire him,…
The 50/30/20 rule is a beginner-friendly budget guide you can start following today. The 50/30/20 rule provides a way to simply break up your after-tax income. With this rule, there are three different “buckets” your money falls into. These buckets are needs, wants and savings. With this rule, 50% of your income will go toward your needs. This includes things that you absolutely have to pay for, such as your rent/mortgage, transportation costs, food and minimum payments on debt. ARE YOU SAVING TOO MUCH MONEY? 5 PLACES TO PUT EXTRA CASH The next category is your wants, which 30% of your…
The personal loan market is growing, in part due to the high cost of living. About 14.5% of borrowers use personal loans for everyday expenses, a MarketWatch Guides survey found. The two more common reasons consumers use personal loans are debt consolidation and home improvements. Nearly 21.2% of personal loans are used to consolidate debt and 20.1% are used to make home improvements. Borrowers are dealing with increasing prices in every industry, from food to building materials to housing costs. To deal with the rising costs, these borrowers turn to personal loans.”Families have already cut back on nonessentials, and there…
Some student loan borrowers who have been making payments for over a decade under income-driven repayment and forgiveness programs have yet to see the forgiveness they were promised. To correct this, the Biden administration is providing that forgiveness, and, as an added bonus, some borrowers are also receiving refunds for past payments, CNBC reported.”Loan servicers were not tracking the number of qualifying payments, and the automatic forgiveness was not occurring,” higher education expert Mark Kantrowitz explained. “As a result, some borrowers have been making payments for years, or even decades, beyond the point at which they should have received forgiveness.”…
Our goal here at Credible Operations, Inc., NMLS Number 1681276, referred to as “Credible” below, is to give you the tools and confidence you need to improve your finances. Although we do promote products from our partner lenders who compensate us for our services, all opinions are our own. The interest rate on a 30-year fixed-rate mortgage is 7.125% as of April 10, which is unchanged from yesterday. Additionally, the interest rate on a 15-year fixed-rate mortgage is 6.125%, which is 0.250 percentage points lower than yesterday. With mortgage rates changing daily, it’s a good idea to check today’s rate…
Medicare expects it will spend more $550 million this year for the controversial anti-Alzheimer’s drug Leqembi and predicts the cost will skyrocket to $3.5 billion in 2025, according to Stat News. The program spent $5.7 billion on drugs such as Ozempic and Mounjaro in 2022, according to the Kaiser Family Foundation. These GLP-1 medications were designed to treat type 2 diabetes but increasingly have been used by those without the condition to lose weight. And these costs are likely to skyrocket in coming years. Medicare has agreed to loosen its rules for paying for some GLP-1 drugs if a patient…
